Pfizer INC

Pfizer reported robust second-quarter 2026 financial results, driven by strong performance in launched and acquired products, leading to an upward revision of its full-year revenue guidance.

Pfizer Inc. reaffirms its full-year 2026 financial guidance for revenues and adjusted diluted EPS following its Chief Financial Officer transition announcement.

Pfizer Inc. announced that Chief Financial Officer Dave Denton will depart on August 15, 2026, to pursue an opportunity in the consumer goods sector, with Cecile Guegan appointed as Interim CFO.

Pfizer Inc. announced robust first-quarter 2026 financial results, driven by a 22% operational revenue growth in launched and acquired products, and reaffirmed its full-year 2026 financial guidance.

Pfizer shareholders re-elected the board of directors and approved executive compensation at the 2026 Annual Meeting.

Pfizer Inc. announced its fourth-quarter and full-year 2025 financial results, reaffirming its full-year 2026 financial guidance and highlighting strong non-COVID portfolio growth.

Pfizer Inc. reported a net loss for the second quarter of 2026, impacted by substantial intangible asset impairments and increased legal costs, though total revenues saw a modest increase.

Pfizer Inc. announced its first quarter 2026 financial results, showing a 5% increase in total revenues to $14.5 billion, driven by strong performance in key biopharmaceutical products.

Pfizer reported a 6% revenue decrease in Q3 2025, primarily due to lower demand for COVID-19 products, while advancing strategic cost-cutting and a major acquisition bid for Metsera.

Pfizer reported a significant increase in second-quarter net income and EPS, driven by strong product performance and ongoing cost realignment efforts, despite headwinds from the IRA Medicare Part D Redesign.

Pfizer's Q1 2025 revenues decreased by 8% due to lower sales of COVID-19 products and the impact of the Inflation Reduction Act, despite growth in other key products.

Pfizer's third-quarter earnings surged, fueled by robust sales of Paxlovid and contributions from the recently acquired Seagen, despite some declines in other key products.

Pfizer reports a 2% revenue decline in 2025, primarily due to reduced COVID-19 product sales, while advancing its pipeline through key acquisitions and cost-reduction initiatives.

Pfizer's 2024 10-K filing highlights a year of revenue growth driven by key products and strategic acquisitions, alongside efforts to improve R&D productivity and maximize operational efficiency.

Pfizer Inc.'s recent 10-K filing outlines the company's registered securities, including common stock and notes, along with details on capital structure and debt obligations.

Albert Bourla, Chairman & CEO and a Director of Pfizer Inc, received 22 shares of common stock on August 14, 2026.

Albert Bourla, Chairman & CEO and a Director of Pfizer Inc, purchased 38,000 shares of common stock on August 12, 2026 for $26.34 per share.

Jennifer B. Damico, SVP & Controller of Pfizer Inc, sold 3,278 shares of common stock on August 5, 2026 for $25.40 per share.

Ronald E Blaylock, a Director of Pfizer Inc, purchased 39,231 shares of common stock on August 5, 2026 for $25.46 per share.

Albert Bourla, Chairman & CEO and a Director of Pfizer Inc, received 24 shares of common stock on July 31, 2026.

Albert Bourla, Chairman & CEO and a Director of Pfizer Inc, received 24 shares of common stock on July 15, 2026.

Pfizer Inc. has filed a Definitive Proxy Statement (DEFA14A) with the SEC, signaling upcoming shareholder matters.

Pfizer reported a 2% operational revenue decline in 2025 but highlighted 6% ex-COVID growth, significant cost savings, and strategic pipeline advancements, while addressing executive compensation concerns.

Pfizer's Annual Meeting of Shareholders will be held virtually on April 24, 2025, with the Board recommending votes for director nominees, ratification of KPMG LLP, advisory approval of executive compensation, and against two shareholder proposals.

Pfizer Inc. will hold its 2025 Annual Meeting of Shareholders virtually on April 24, 2025, and has provided information on how to learn more and vote.

Pfizer Inc. disseminates its proxy statement via LinkedIn, Facebook, Yahoo! Finance, display advertising, and Google Search Advertising on April 10, 2025.

Pfizer announces its virtual annual meeting and highlights a year of transformative change and innovation in 2024, with a focus on R&D realignment and shareholder value.

Pfizer Inc. filed its Form 13F for the quarter ended March 31, 2026, detailing its institutional investment holdings.

Pfizer Inc. has filed its Form 13F-HR, revealing its equity holdings totaling over $236 million across 21 positions as of December 31, 2025.

Pfizer Inc. filed its Form 13F-HR, revealing its equity holdings totaling over $437 million as of September 30, 2025.

Pfizer Inc. has filed its Form 13F-HR, revealing its institutional investment holdings totaling over $576 million as of June 30, 2025.

Pfizer Inc. reports its holdings for the quarter ended March 31, 2025, with a total portfolio value of approximately $500.8 million across 24 holdings.

Pfizer Inc's latest 13F filing discloses a diverse investment portfolio with a total value of over $2.5 billion as of December 31, 2024.

Pfizer Inc. reported a decrease in its beneficial ownership of Allogene Therapeutics, Inc. common stock to 9.0%, solely due to an increase in Allogene's outstanding shares.

Pfizer Inc. has announced the completion of its divestment from Haleon plc, ceasing to be a beneficial owner of the consumer healthcare company's shares following a secondary offering and a share buyback.

Pfizer Inc. has announced the final divestment of its entire 7.3% beneficial ownership in Haleon plc through a secondary block trade offering of 617.55 million shares and a concurrent share buyback by Haleon of 44 million shares, totaling approximately $220 million.

Pfizer Inc. filed an Amendment No. 13 to its Schedule 13D, disclosing its continued beneficial ownership of 7.3% of Haleon plc's Ordinary Shares and the departure of its nominated director, Mr. Supran, following the termination of the Pfizer Relationship Agreement.

Pfizer Inc. has significantly reduced its beneficial ownership in Haleon plc to approximately 7.3% after completing a secondary offering of 700 million Ordinary Shares, generating substantial proceeds.

Pfizer Inc. announced an amendment to its Schedule 13D, detailing a secondary offering of 700 million Haleon plc Ordinary Shares, which will reduce its beneficial ownership to less than 10% and terminate its contractual right to nominate directors to Haleon's Board.

Pfizer Inc. has reported a beneficial ownership of 3,442,940 shares, representing 3.3% of the outstanding common stock of ORIC Pharmaceuticals, Inc. as of March 31, 2026.

The Vanguard Group has reported zero beneficial ownership in Pfizer Inc. common stock following an internal realignment that disaggregated reporting responsibilities.

Pfizer Inc. has filed an amended Schedule 13G, disclosing a 2.3% beneficial ownership in Q32 Bio Inc., following a merger involving Homology Medicines.

Pfizer Inc. and its affiliate, Pfizer Ventures (US) LLC, filed an amended Schedule 13G, disclosing a combined beneficial ownership of 3.0% in NEXTCURE, INC. common stock as of December 31, 2025.

Pfizer Inc. has reported a 4.6% beneficial ownership stake in Zura Bio Limited's Class A Ordinary Shares as of December 31, 2024, according to a recent SEC Schedule 13G filing.

Pfizer Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 3.6% of Cardiff Oncology, Inc.'s common stock as of December 31, 2024.